MannKind | MNKD - 净收入

金融业

USD

USD 792.18M

现金及等价物

USD 74.88M

USD 33.65M

USD 291.58M

USD 171.03M

USD 119.91M

USD -69.24M

USD 17.92M

407

EPS每股收益

USD 0.01

股本和储备

USD -51.02M

USD 78.31M

债务利息支出

USD 13.87M

USD 2.63M

USD 548.44M

USD 667.9M

USD -15.95M

USD 119.65M

USD -69.24M

普通股股本

USD 307.83M

303.7

USD -20.93M

USD 111.96M

销售和管理费用

USD 29.09M

USD 35.31M

贸易债权人

USD 9.03M

应收帐款人

USD 38.37M

	净收入	更改		日
Adma Biologics	USD 49.38M		12.95M	2025-12
BioCryst Pharmaceuticals	USD 245.84M		232.95M	2025-12
Eli Lilly	USD 6.64B		1.05B	2025-12
Halozyme Therapeutics	USD -141.59M		316.82M	2025-12
Insmed	USD -328.48M		41.54M	2025-12
Karyopharm Therapeutics	USD -30.78M		1.29M	2024-12
MacroGenics	USD -14.16M		30.98M	2025-12
MannKind	USD -15.95M		23.93M	2025-12
Merck	USD 2.96B		2.82B	2025-12
Minerva Neurosciences	USD 1.44M		21.07M	2024-12
Novavax	USD 17.53M		219.91M	2025-12
Novo Nordisk	DKK 4.03B		25.01B	2025-06
Pfizer	USD -1.65B		5.19B	2025-12
Sanofi	EUR -801M		3.6B	2025-12
Xencor	USD -6.65M		626K	2025-12